Alioth Bio Announces Completion of Nearly RMB 100 Million Series A Financing to Advance Membrane Filtration Solutions for Pharmaceutical Manufacturing

VCBeat has learned that Alioth Biotech (Shanghai) Co., Ltd. (“Alioth”) recently announced the completion of its nearly RMB 100 million Series A financing round. The round was co-led by Matrix Partners China and Legend Capital, with participation from investors including Shanghai Yishui Liushan. Yishan Capital served as the strategic financial advisor for this financing. The proceeds will be used by AliothConstruction of Membrane Material R&D Center and Construction & Scale-up of Production Base for Pharmaceutical Process Filters, andExpansion of the Professional Talent Teamand other aspects.

ALIOTH, established in 2021, specializes in the development and application of supporting technical products for pharmaceutical manufacturing processes, and is committed to providing high-quality separation and purification solutions that comply with domestic and international regulatory requirements for pharmaceutical companies.

ALIOTH has established its own production bases in Shanghai Lingang and Hangzhou in accordance with GMP requirements. The company is equipped with process development laboratories, validation laboratories, and a filtration product R&D center, and has built an R&D team led by membrane technology scientists. These initiatives are designed to better safeguard the supply chain security of Chinese pharmaceutical enterprises, assist users in optimizing drug R&D and manufacturing processes, and enhance the safety of pharmaceutical production. Upholding the corporate values of collaboration, integrity, respect, and responsibility, ALIOTH supports the innovative development of China’s pharmaceutical industry. True to the meaning behind its name, ALIOTH is committed to becoming a shining star in the global pharmaceutical manufacturing industry chain.

Jia Qijun, Founder and Chairman of ALIOTH“With the booming development of China’s biopharmaceutical industry, the upstream bioprocessing market has witnessed rapid growth. As a core component of downstream bioprocessing, membrane filtration saw its global market size exceed RMB 40 billion in 2021, while the domestic market reached nearly RMB 4 billion. Membrane filtration technology for bioprocessing spans two key areas outlined in the ‘Made in China 2025’ strategy: ‘New Materials’ and ‘Biomedicine.’ Effectively facilitating technological translation and industrial integration between these two fields is crucial to overcoming bottleneck technologies in this sector. Since its inception, ALIOTH has actively assembled a team of experts in relevant fields. Adhering to the principles of innovation-driven development and quality first, the company aims to create high-quality membrane filtration products and solutions with independent intellectual property rights, striving to contribute to the advancement of China’s high-end manufacturing and biopharmaceutical industries.”

Sun Linghao, Managing Director at Matrix Partners China“ALIOTH represents another early-stage investment in our life sciences tools portfolio. The company’s core team hails entirely from top multinational corporations specializing in biopharmaceutical membrane filtration. Shortly after its establishment, ALIOTH set up compliant manufacturing facilities in Lingang, Shanghai, and Xiasha, Hangzhou, and successfully completed product validation with multiple mainstream clients. In the post-pandemic era, we believe that a deep understanding of customer processes and R&D capabilities in foundational materials will be the core drivers of long-term competitiveness. We look forward to the ALIOTH team continuing to deliver high-quality products and contributing to the security and stability of China’s upstream core supply chain for the biopharmaceutical industry.”

Wang Jianfei, Managing Director of Legend CapitalIt stated: “The rapid development of China’s pharmaceutical industry has boosted market demand for critical filtration consumables in drug manufacturing. International trade disputes and the COVID-19 pandemic have created an urgent need among domestic biopharmaceutical companies for stable supply chains, while cost pressures from centralized volume-based procurement are driving local pharmaceutical firms to seek cost-effective filtration process solutions. Currently, foreign companies still hold a significant share of the pharmaceutical filtration consumables market, leaving substantial room for growth for domestic enterprises. The founding team and core members of ALIOTH work together with strong synergy and execution capability. With over a decade of deep engagement in the biopharmaceutical consumables industry, they are well-versed in pharmaceutical processes and filtration technologies, understand market demands and customer pain points, and possess extensive experience in lean production management. Several of the company’s products have been initially launched to the market, receiving positive customer feedback. We believe that, with capital support, ALIOTH will accelerate its development and continuously strive for improvement. Legend Capital will continue to provide assistance in optimizing corporate development strategy, supporting management and operations, and facilitating industrial connections and collaborations.”

Market Data Source: Allied Market Research Market Research Report

Matrix Partners China, founded in 2008, is a leading venture capital firm in the industry with a long-term focus on early-stage and early-growth investments. It specializes in investing in new technologies, hard tech, industrial digitalization, healthcare, frontier technologies, and new consumer sectors. To date, it has invested in more than 700 companies, including XPeng Motors, Li Auto, Futu Securities, Chehaoduo Group, Ele.me, Ronbay Technology, XGIMI, Momo, PingCAP, Peijia Medical, Beisen, Zihai Guo, Jian Ai, Mega Robotics, Enhe Biopharma, and Adjuvix.

Legend Capital was established in April 2001 as a fund management company under Legend Holdings, specializing in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, Legend Capital drives innovative corporate growth, delivering consistent strong investment returns across multiple sectors while advancing China’s industrial progress and social development. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Wealth with Integrity” and actively fulfills its social responsibilities.